Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Acalabrutinib

Subscribe to access the full database, or Try it Free
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02029443 ↗	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1/Phase 2	2014-01-30	This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02112526 ↗	Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-07	To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
NCT02157324 ↗	Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-18	This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma, LLC	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma BV	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Acalabrutinib

Condition Name

Chart
Table

Condition Name for Acalabrutinib
Intervention	Trials
Chronic Lymphocytic Leukemia	30
Mantle Cell Lymphoma	22
Small Lymphocytic Lymphoma	13
Diffuse Large B Cell Lymphoma	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Acalabrutinib
Intervention	Trials
Lymphoma	59
Leukemia, Lymphocytic, Chronic, B-Cell	44
Leukemia, Lymphoid	42
Leukemia	37
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Acalabrutinib

Trials by Country

Map
Table

Trials by Country for Acalabrutinib
Location	Trials
United States	463
Canada	41
United Kingdom	33
Poland	24
France	19
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Acalabrutinib
Location	Trials
Texas	36
California	32
New York	30
Washington	24
Ohio	24
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	15
Phase 2/Phase 3	1
[disabled in preview]	82
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase	Trials
Recruiting	60
Active, not recruiting	22
Completed	22
[disabled in preview]	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Chart
Table

Sponsor Name for Acalabrutinib
Sponsor	Trials
Acerta Pharma BV	44
AstraZeneca	44
National Cancer Institute (NCI)	17
[disabled in preview]	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Acalabrutinib
Sponsor	Trials
Industry	113
Other	91
NIH	18
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Moodys

Medtronic

Harvard Business School

Boehringer Ingelheim

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.